Compound News and Research

RSS

Polymer-based medical implants can produce harmful free radicals

A polymer is a mesh of chains, which slowly break over time due to the pressure from ordinary wear and tear. When a polymer is squeezed, the pressure breaks chemical bonds and produces free radicals: ions with unpaired electrons, full of untapped energy. These molecules are responsible for aging, DNA damage and cancer in the human body.

3 Mar 2012

CLR01 blocks toxic aggregations of proteins in mouse model of Parkinson's

Millions of people suffer from Parkinson's disease, a disorder of the nervous system that affects movement and worsens over time. As the world's population ages, it's estimated that the number of people with the disease will rise sharply. Yet despite several effective therapies that treat Parkinson's symptoms, nothing slows its progression.

2 Mar 2012

Study offers hope for novel approach to prevent AD

As scientists struggle to find an effective way to prevent Alzheimer's disease, researchers at the University of Wisconsin-Madison may have found a new approach to interrupting the process that leads to the devastating disease.

2 Mar 2012

Positive results from AltheRx Solabegron Phase II study on overactive bladder

AltheRx Pharmaceuticals, a privately-held clinical development company, presented positive results from its Phase II study of Solabegron in overactive bladder (OAB) at the European Association of Urology Congress in Paris.

1 Mar 2012

La Selva geothermal system contaminated with arsenic

Monitoring the construction of wells, avoid over-exploiting cold groundwater close to hot groundwater, and controlling mineral water extraction. These are the recommendations from the Polytechnic University of Catalonia and the University of Barcelona, after analysing the contamination of La Selva geothermal system, above all by arsenic pollution.

1 Mar 2012

New data on how genes and age influence AD plaque deposition

When 225 researchers from around the world convened in Miami to exchange the latest on β amyloid positron emission tomography in January, there was a palpable sense of urgency. At the 6th Annual Human Amyloid Imaging (HAI) Conference, the possibility of approval, potentially within months, of the first amyloid-scanning compound for clinical use hung over the room.

1 Mar 2012

HDAC2 enzyme could be a potential target for new Alzheimer's drugs

MIT neuroscientists have shown that an enzyme overproduced in the brains of Alzheimer's patients creates a blockade that shuts off genes necessary to form new memories. Furthermore, by inhibiting that enzyme in mice, the researchers were able to reverse Alzheimer's symptoms.

1 Mar 2012

Coloplast's InterDry textile receives Most Innovative New Product award from NAFC

The National Association For Continence (NAFC) presented the Most Innovative New Product award to Coloplast for its new product, InterDry Ag, a textile that helps reduce the risk of moisture-associated skin damage, most often diagnosed as intertriginous dermatitis (intertrigo).

29 Feb 2012

EpiCept fourth quarter revenue decreases to $0.2 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2011, and provided an update on the Company's key business initiatives.

29 Feb 2012

Cannabinoids may be a target for new strategies in cancer treatment

Cannabis-like substances that are produced by the body have both therapeutic and harmful properties, besides their well-known intoxicating effects, and the body's cannabinoid system may be a target for new strategies in cancer treatment.

29 Feb 2012

Chemically altered osteoporosis drug may fight malaria

A chemically altered osteoporosis drug may be useful in fighting malaria, researchers report in a new study. Unlike similar compounds tested against other parasitic protozoa, the drug readily crosses into the red blood cells of malaria-infected mice and kills the malaria parasite. The drug works at very low concentrations with no observed toxicity to the mouse.

27 Feb 2012

EMA acceptance of peginesatide MAA triggers $5M milestone payment to Affymax

Affymax, Inc. today announced that it will receive a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize peginesatide.

27 Feb 2012

H2S transforms dental pulp stem cells into liver cells

Japanese scientists have found that the odorous compound responsible for halitosis - otherwise known as bad breath - is ideal for harvesting stem cells taken from human dental pulp.

27 Feb 2012

The Lancet publishes Takeda's TAK-875 Phase 2 data on type 2 diabetes

Phase 2 clinical data of an investigational type 2 diabetes therapy, TAK-875 of Takeda Pharmaceutical Company Limited, were published online first in The Lancet.

27 Feb 2012

Exelixis announces cabozantinib preclinical data on pancreatic cancer

Exelixis, Inc. today announced the company's lead compound, cabozantinib, is highlighted in a new peer-reviewed publication demonstrating that simultaneous inhibition of MET and VEGF signaling reduces tumor invasiveness and metastasis in preclinical models of pancreatic cancer.

26 Feb 2012

Bath salts mimic effects of two powerful narcotics

The street drug commonly referred to as "bath salts" is one of a growing list of synthetic and unevenly regulated narcotics that are found across the United States and on the Internet. New research on this potent drug paints an alarming picture, revealing that bath salts pack a powerful double punch, producing combined effects similar to both methamphetamine (METH) and cocaine.

24 Feb 2012

Medivir reports net sales of SEK 698.6M for fiscal 2011

Today, Medivir AB, a research-based specialty pharmaceutical company focused on infectious diseases, is publishing its Interim Report for the period 1 January - 31 December and its operational report for the fourth quarter of 2011.

23 Feb 2012

Scientists design compounds that act against myotonic dystrophy type 1 RNA

While RNA is an appealing drug target, small molecules that can actually affect its function have rarely been found. But now scientists from the Florida campus of The Scripps Research Institute have for the first time designed a series of small molecules that act against an RNA defect directly responsible for the most common form of adult-onset muscular dystrophy.

23 Feb 2012

Researchers discover how mTOR protein leads to cancer metastasis

Uncovering the network of genes regulated by a crucial molecule involved in cancer called mTOR, which controls protein production inside cells, researchers at the University of California, San Francisco (UCSF) have discovered how a protein "master regulator" goes awry, leading to metastasis, the fatal step of cancer.

23 Feb 2012

Chemists build light-controlled neural inhibitor

The notion of a pain switch is an alluring idea, but is it realistic? Well, chemists at LMU Munich, in collaboration with colleagues in Berkeley and Bordeaux, have now shown in laboratory experiments that it is possible to inhibit the activity of pain-sensitive neurons using an agent that acts as a photosensitive switch. For the LMU researchers, the method primarily represents a valuable tool for probing the neurobiology of pain.

23 Feb 2012